Trial Profile
A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 20 Jan 2024 Results of pooled analysis from NCT02870920 and NCT02879318; investigating the incidence of CHIP in ctDNA from patients with gastrointestinal (GI) cancers and explored its association with outcomes and adverse events , presented at the 2024 Gastrointestinal Cancers Symposium
- 06 Jun 2023 Results assessing temporal evolution of RAS mutation status in metastatic colorectal cancer patients, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Results of a post-hoc exploratory analysis assessing the role of plasma ARG in predicting response to ICI in patients with refractory mCRC presented at the 59th Annual Meeting of the American Society of Clinical Oncology